JGC
TARA icon

J. Goldman & Co’s Protara Therapeutics TARA Stock Holding History

J. Goldman & Co’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$516K Sell
135,000
-721,247
-84% -$3.43M 0.01% 552
2026
Q1 		$4.46M Buy
+856,247
New +$5.07M 0.13% 200
2025
Q4 		– Sell
-100,350
Closed -$437K – 736
2025
Q3 		$437K Sell
100,350
-27,000
-21% -$87.4K 0.01% 388
2025
Q2 		$386K Sell
127,350
-18,991
-13% -$65.5K 0.01% 396
2025
Q1 		$623K Buy
146,341
+4,593
+3% +$20.5K 0.02% 393
2024
Q4 		$748K Buy
+141,748
New +$458K 0.02% 349

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

J. Goldman & Co's TARA Position: Q2 2026 in Review

J. Goldman & Co reduced its Protara Therapeutics (TARA) stake by 84% in Q2 2026, selling an estimated $3.43M and leaving 135,000 shares worth $516K. The position accounts for 0.01% of the portfolio, ranked #552.

J. Goldman & Co first reported a position in TARA in Q4 2024 and has held it in 6 quarters since. The position peaked at $4.46M in Q1 2026. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • J. Goldman & Co held 135,000 shares of Protara Therapeutics worth $516K as of Q2 2026.
  • J. Goldman & Co sold 721,247 Protara Therapeutics shares in Q2 2026, an estimated $3.43M.
  • Protara Therapeutics made up 0.01% of J. Goldman & Co's portfolio in Q2 2026, its #552 holding.
  • J. Goldman & Co first reported a position in Protara Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • J. Goldman & Co's Protara Therapeutics position peaked at $4.46M in Q1 2026.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.